Maximising the potential of Clinical Trials with best practice direct to patient distribution
Join Almac expert and Supply Chain Solutions Manager, David Ergott, for a deep dive into the realm of DCTs and the evolving role direct to patient distribution is playing in shaping a new, patient-focused chapter in drug development.
Decentralised clinical trials (DCTs) are transforming drug development as we know it. Democratising research, enhancing diversity, reducing participant burden, improving access, speeding up recruitment and optimising efficiencies.
A thought leader in his field, David Ergott will guide delegates through the various direct to patient distribution models available. He’ll cover how these models can be crafted to cater to diverse programme requirements and harnessed in myriad ways, including strategically to support studies incorporating frequent dosing and/or remote monitoring and as contingency to safeguard supply during crises.
Key Learning Objectives:
- Discover what a DCT is and the benefits of utilising a decentralised approach.
- Understand how direct to patient distribution supports DCTs.
- Learn from best practice examples for implementing direct to patient distribution.
- Explore the regulatory landscape and the role of Clinical Pharmacists.